Antibody Titers Before and After a Third Dose of the BNT162b2 Vaccine in Older Adults | Geriatrics | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: October 19, 2021.

Published Online: November 5, 2021. doi:10.1001/jama.2021.19885

Corresponding Author: Salomon M. Stemmer, MD, Davidoff Cancer Center, Rabin Medical Center, Belinson Hospital, Sackler Faculty of Medicine, Tel Aviv University, 39 Jabotinsky St, Petah Tikva 49100, Israel (salomon.stemmer@gmail.com).

Author Contributions: Dr S. M. Stemmer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Eliakim-Raz and Leibovici-Weisman contributed equally to this work.

Concept and design: Eliakim-Raz, Leibovici-Weisman, S. M. Stemmer.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: Eliakim-Raz, Leibovici-Weisman, A. Stemmer, S. M. Stemmer.

Statistical analysis: A. Stemmer, S. M. Stemmer.

Obtained funding: S. M. Stemmer.

Administrative, technical, or material support: Eliakim-Raz, Leibovici-Weisman, Ness, Awwad, Ghantous, S. M. Stemmer.

Supervision: Eliakim-Raz, Leibovici-Weisman, S. M. Stemmer.

Conflict of Interest Disclosures: Dr S. M. Stemmer reported receiving research grants (to his institution) from CAN-FITE, AstraZeneca, BioLineRX, BMS, Clovis Oncology, CTG Pharma, Exelixis, GEICAM, Halozyme, Incyte, Lilly, Moderna, Teva Pharmaceuticals, and Roche and owning stocks and options in CTG Pharma, DocBoxMD, TyrNovo, VYPE, Cytora, and CAN-FITE. No other disclosures were reported.

Data Sharing Statement: The data sets generated during this study are available from the corresponding author on request.

Additional Contributions: We thank Avital Bareket-Samish, PhD, BioInsight Ltd, for medical editing support. She received financial compensation for her contribution.

References
1.
Walsh  EE , Frenck  RW  Jr , Falsey  AR ,  et al.  Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates.   N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906PubMedGoogle ScholarCrossref
2.
Levin  EG , Lustig  Y , Cohen  C ,  et al.  Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months.   N Engl J Med. Published online October 6, 2021. doi:10.1056/NEJMoa2114583PubMedGoogle Scholar
3.
Benotmane  I , Gautier  G , Perrin  P ,  et al.  Antibody response after a third dose of the MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses.   JAMA. 2021;326(11):1063-1065. doi:10.1001/jama.2021.12339PubMedGoogle ScholarCrossref
4.
Bar-On  YM , Goldberg  Y , Mandel  M ,  et al.  Protection of BNT162b2 vaccine booster against Covid-19 in Israel.   N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255PubMedGoogle ScholarCrossref
5.
Harvey  RA , Rassen  JA , Kabelac  CA ,  et al.  Association of SARS-CoV-2 seropositive antibody test with risk of future infection.   JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366PubMedGoogle ScholarCrossref
6.
Sahin  U , Muik  A , Derhovanessian  E ,  et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.   Nature. 2020;586(7830):594-599. doi:10.1038/s41586-020-2814-7PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close